NCT04906096 - Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2027

Conditions

Primary Central Nervous System LymphomaNon-Hodgkin Lymphoma of Extranodal Site

Interventions

DRUG

PAXALISIB

Each study treatment cycle lasts 28 days, up to 24 months. Oral, daily, dosage per protocol

Trial Locations (2)

NOT_YET_RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana Farber Cancer Institute, Boston